Press Releases | PTC Therapeutics, Inc.

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Year

Jul 24, 2017

PTC Therapeutics Announces Promotion of Dr. Joseph McIntosh to Senior Vice President and Head of Clinical Development

SOUTH PLAINFIELD, N.J. , July 24, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the promotion of Joseph McIntosh , M.D. to Senior Vice President and Head of Clinical Development. Dr. McIntosh will be responsible for all aspects of Clinical Development across PTC's

Jul 18, 2017

PTC Therapeutics Announces Publication of Data from ACT DMD in The Lancet

SOUTH PLAINFIELD, N.J. , July 18, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the publication of the results of the ACT DMD trial study ataluren, the only treatment for the underlying cause of nonsense mutation Duchene muscular dystrophy (nmDMD), in the current issue

Jul 01, 2017

Preliminary Phase 2 Data from Spinal Muscular Atrophy Program Presented at CureSMA Conference

-- RG7916 demonstrated ~400% increase in SMN2 full length/Δ7 mRNA ratio --
-- RG7916 demonstrated a favorable preliminary safety profile and was generally well tolerated in Type 2/3 SMA patients --

Jun 30, 2017

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J. , June 30, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 27, 2017 it approved non-statutory stock options to purchase an aggregate of 74,750 shares of its common stock to seven new employees.

Jun 22, 2017

New Analyses of Translarna™ (ataluren) Data from ACT DMD Presented at the 12th Annual European Pediatric Neurology Society Congress

SOUTH PLAINFIELD, N.J. , June 22, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of new analyses utilizing alternative methods to understand the progression of Duchenne muscular dystrophy and the benefits of Translarna in nonsense mutation Duchenne

Jun 06, 2017

PTC Therapeutics Announces FDA Advisory Committee Meeting for Ataluren for the Treatment of Nonsense Mutation Dystrophinopathy

- September 28th is FDA's Tentative Date for Advisory Committee Meeting -

Jun 05, 2017

PTC Therapeutics Announces Executive Promotions

SOUTH PLAINFIELD, N.J. , June 5, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointments of Marcio Souza to Chief Operating Officer and Christine Utter to Principal Financial Officer and Treasurer. "I am extremely pleased to announce these promotions.

Jun 02, 2017

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J. , June 2, 2017 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on May 30, 2017 it approved non-statutory stock options to purchase an aggregate of 46,000 shares of its common stock to seven new employees.

May 23, 2017

New Analysis of ACT DMD Placebo Data on Corticosteroids Presented at International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting

- Analysis includes data from ACT DMD on deflazacort and prednisone/prednisolone -

May 19, 2017

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J. , May 19, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on May 17, 2017 it approved non-statutory stock options to purchase 46,500 shares of its common stock to ten new employees. The awards were made pursuant to the NASDAQ inducement grant

Pagination

First page
Previous page
…
Page 31
Page 32
Current page 33
Page 34
Page 35
…
Next page
Last page